AnaptysBio (NASDAQ:ANAB) Price Target Raised to $33.00

AnaptysBio (NASDAQ:ANAB) had its target price lifted by UBS Group from $23.00 to $33.00 in a report issued on Wednesday morning, Benzinga reports. The firm currently has a neutral rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently weighed in on ANAB. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a report on Wednesday, August 14th. Guggenheim raised their target price on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price target on shares of AnaptysBio in a report on Thursday, September 26th. JPMorgan Chase & Co. increased their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, Truist Financial boosted their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $55.73.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $21.68 on Wednesday. AnaptysBio has a 52-week low of $13.36 and a 52-week high of $41.31. The business has a fifty day moving average of $34.28 and a two-hundred day moving average of $29.82. The stock has a market cap of $594.77 million, a PE ratio of -3.41 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The firm had revenue of $10.97 million for the quarter, compared to the consensus estimate of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. Analysts predict that AnaptysBio will post -6.84 earnings per share for the current year.

Insider Activity at AnaptysBio

In related news, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the transaction, the insider now owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock worth $892,936 over the last ninety days. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio in the first quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in AnaptysBio during the 1st quarter worth approximately $265,000. Susquehanna Fundamental Investments LLC acquired a new stake in AnaptysBio during the 1st quarter worth approximately $1,221,000. Acadian Asset Management LLC bought a new position in AnaptysBio in the first quarter valued at approximately $420,000. Finally, Platinum Investment Management Ltd. acquired a new position in shares of AnaptysBio in the first quarter valued at approximately $1,490,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.